[미국특허]
Methods for treatment of ankylosing spondylitis using TNF alpha antibodies
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
A61K-039/00
C07K-016/24
출원번호
US-0012787
(2008-02-04)
등록번호
US-9279015
(2016-03-08)
발명자
/ 주소
Wong, Robert L.
Kupper, Hartmut
Luo, Michelle P.
Sieper, Joachim
Davis, John C.
Maksymowych, Walter P.
출원인 / 주소
Wong, Robert L.
대리인 / 주소
Foley Hoag LLP
인용정보
피인용 횟수 :
2인용 특허 :
38
초록▼
The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs a
The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of ankylosing spondylitis in a subject.
대표청구항▼
1. A method of treating a subject having early axial spondyloarthritis (SpA), comprising administering to the subject an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, to the subject, such that early axial spondyloarthritis is treated. 2. The method of claim 1, wherein the
1. A method of treating a subject having early axial spondyloarthritis (SpA), comprising administering to the subject an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, to the subject, such that early axial spondyloarthritis is treated. 2. The method of claim 1, wherein the human anti-TNFα antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 3. The method of claim 1, wherein a 40 mg dose of the human anti-TNFα antibody, or antigen-binding portion thereof, is subcutaneously administered biweekly to the subject. 4. The method of claim 1, wherein the human anti-TNFα antibody, or an antigen-binding portion thereof, comprises a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a heavy chain variable region (HCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8. 5. The method of claim 1, wherein the human anti-TNFα antibody, or antigen-binding portion thereof, is adalimumab. 6. The method of claim 5, wherein a 40 mg dose of adalimumab is subcutaneously administered biweekly to the subject. 7. A method of treating a subject having early axial spondyloarthritis (SpA), comprising selecting a subject having early axial SpA and administering to the subject an isolated human anti-TNFα antibody, or an antigen-binding portion thereof, to the subject, such that early axial spondyloarthritis is treated, wherein the human anti-TNFα antibody, or an antigen-binding portion thereof, comprises a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a heavy chain variable region (HCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8. 8. The method of claim 7, wherein the subject is selected before occurrence of radiographic sacroiliitis. 9. The method of claim 7, wherein the human anti-TNFα antibody, or an antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 10. The method of claim 7, wherein the human anti-TNFα antibody, or an antigen-binding portion thereof, is adalimumab.
Zabrecky,George, Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis.
Salfeld,Jochen G.; Allen,Deborah J.; Hoogenboom,Hendricus R. J. M.; Kaymakcalan,Zehra; Labkovsky,Boris; Mankovich,John A.; McGuinness,Brian T.; Roberts,Andrew J.; Sakorafas,Paul; Schoenhaut,David; Va, Human antibodies that bind human TNFα.
Salfeld Jochen G. ; Allen Deborah J.,GBX ; Hoogenboom Hendricus R. J. M. ; Kaymakcalan Zehra ; Labkovsky Boris ; Mankovich John A. ; McGuinness Brian T.,GBX ; Roberts Andrew J.,GBX ; Sakorafas Paul ;, Human antibodies that bind human TNF.alpha..
Salfeld Jochen G. ; Allen Deborah J.,GBX ; Hoogenboom Hendricus R. J. M.,BEX ; Kaymakcalan Zehra ; Labkovsky Boris ; Mankovich John A. ; McGuinness Brian T.,GBX ; Roberts Andrew J.,GBX ; Sakorafas Pa, Human antibodies that bind human TNF.alpha..
Salfeld, Jochen G.; Allen, Deborah J.; Hoogenboom, Hendricus R. J. M.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Schoenhaut,, Human antibodies that bind human TNFa.
Salfeld, Jochen G.; Allen, Deborah J.; Hoogenboom, Hendricus R. J. M.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Human antibodies that bind human TNFα.
Salfeld, Jochen G.; Allen, Deborah J.; Hoogenboom, Hendricus R. J. M.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Human antibodies that bind human TNFα.
Salfeld, Jochen G.; Allen, Deborah J.; Hoogenboom, Hendricus R. J. M.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Human antibodies that bind human TNFα.
Salfeld, Jochen G.; Mankovich, John A.; Allen, Deborah J.; Hoogenboom, Hendricus R.J.M.; Labkovsky, Boris; McGuinness, Brian T.; Sakorafas, Paul; White, Michael; Wilton, Alison J.; Kaymakcalan, Zehra; Roberts, Andrew J.; Schoenhaut, David; Vaughan, Tristan J., Human antibodies that bind human TNFα and methods of using same.
Maksymowych, Walter P.; Wong, Robert L., Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers.
Salfeld, Jochen G.; Allen, Deborah J.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Hoogenboom, Hendricus R. J. M.; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa.
Salfeld, Jochen G.; Allen, Deborah J.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Hoogenboom, Hendricus R. J. M.; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα.
Le Junming (Jackson Heights NY) Vilcek Jan (New York NY) Dadonna Peter (Palo Alto CA) Ghrayeb John (Thorndale PA) Knight David (Berwyn PA) Siegel Scott A. (Westborough MA), Methods of treating TNF-a
상세보기
Salfeld, Jochen G.; Allen, Deborah J.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Hoogenboom, Hendricus R. J. M.; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Methods of treating disorders using human antibodies that bind human TNFα.
Armour Kathryn Lesley,GB3 ; Carr Francis Joseph,GB3 ; Old Lloyd J. ; Stockert Elisabeth ; Welt Sydney ; Kitamura Kunio ; Garin-Chesa Pilar,DEX, Recombinant human anti-Lewis Y antibodies.
Moodie, Rachel; Hyland, Elizabeth, Methods of treating Crohn's disease or ulcerative colitis using an induction dosing regimen comprising anti-TNF-alpha antibody.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.